Abstract
Melanoma has been increasing in white populations. Incidence rates rise steeply in women until about age 50, suggesting oestrogen as a possible risk factor. Oestrogens can increase melanocyte count and melanin content and cause hyperpigmentation of the skin. We examined prospectively the association between oral contraceptive (OC) use and diagnoses of superficial spreading and nodular melanoma among 183 693 premenopausal white women in the Nurses’ Health Study (NHS) and the Nurses’ Health Study II (NHS II) cohorts. One hundred and forty six cases were confirmed in NHS during follow-up from 1976 to 1994, and 106 cases were confirmed in NHS II from 1989 to 1995. Skin reaction to sun exposure, sunburn history, mole counts, hair colour, family history of melanoma, parity, height and body mass index were also assessed and included in logistic regression models. A significant twofold increase in risk of melanoma (relative risk (RR) = 2.0, 95% confidence interval (CI) 1.2–3.4) was observed among current OC users compared to never users. Risk was further increased among current users with 10 or more years of use (RR = 3.4, 95% CI 1.7–7.0). Risk did not appear elevated among past OC users, even among those with longer durations of use, and risk did not decline linearly with time since last use. In conclusion, risk of premenopausal melanoma may be increased among women who are current OC users, particularly among those with longer durations of use. Further research is needed to determine whether low-dose oestrogen pills in particular are associated with an increase in risk and to describe possible interactions between OC use and sun exposure or other risk factors for melanoma.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Armstrong, BK & English, DR (1996) Cutaneous malignant melanoma. In: Cancer Epidemiology and Prevention, 2nd edn, Schottenfeld D and Fraumeni JF (ed), pp. 1281–1312. Oxford University Press: New York
Bain, C, Hennekens, CH, Speizer, FE, Rosner, B, Willett, W & Belanger, C (1982) Oral contraceptive use and malignant melanoma. J Natl Cancer Inst 68: 537–539.
Beral, V, Ramcharan, S & Faris, R (1977) Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36: 804–809.
Beral, V, Evans, S, Shaw, H & Milton, G (1984) Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 50: 681–685.
Chaudhuri, PK, Walker, MJ, Briele, HA, Beattie, CW & Das Gupta, TK (1980) Incidence of estrogen receptors in benign nevi and human malignant melanoma. JAMA 244: 791–793.
Cocconi, G, Bella, M, Calabresi, F, Tonato, M, Canaletti, R, Boni, C, Buzzi, BG, Corgna, E, Costa, P, Lottici, R, Papadia, F, Sofra, MC & Bacchi, M (1992) Treatment of metastatic malignant melanoma with decarbazine plus tamoxifen. N Engl J Med 327: 517–523.
Colditz, GA, Manson, JE & Hankinson, SE (1990) The Nurses’ Health Study: 20-year contribution to the understanding of health among women. J Women Health 6: 49–62.
Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–1727.
D’Agostino, RB, Lee, MLT, Belanger, AJ, Cupples, LA, Anderson, K & Kannel, WB (1990) Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 9: 1501–1515.
DerSimonian, R & Laird, N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7: 177–188.
Fisher, RI, Heifeld, JP & Lippman, ME (1976) Oestrogen receptors in human malignant melanoma. Lancet 2: 337–339.
Gallagher, RP, Elwood, JM, Hill, GB, Coldman, AJ, Threlfall, WJ & Spinelli, JJ (1985) Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br J Cancer 52: 901–907.
Hannaford, PC, Villard-Mackintosh, L, Vessey, MP & Kay, CR (1991) Oral contraceptives and malignant melanoma. Br J Cancer 63: 430–433.
Helmrich, SP, Rosenberg, L, Kaufman, DW, Miller, DR, Schottenfeld, D, Stolley, PD & Shapiro, S (1984) Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst 72: 617–620.
Holly, EA, Weiss, NS & Liff, JM (1983) Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 70: 827–831.
Holly, EA, Cress, RD & Ahn, DK (1995) Cutaneous melanoma in women: reproductive factors and oral contraceptive use. Am J Epidemiol 141: 943–950.
Holman, CDJ, Armstrong, BK & Heenan, PJ (1984) Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 50: 673–680.
Holman, CDJ, Armstrong, BK & Heenan, PJ (1986) Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 76: 403–414.
Hunter, DJ, Manson, JE, Colditz, GA, Chasan-Taber, L, Troy, L, Stampfer, MJ, Speizer, FE & Willett, WC (1997) Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 56: 373–378.
Jelinek, JE (1970) Cutaneous side effects of oral contraceptive. Arch Dermatol 101: 181–186.
Le, MG, Cabanes, PA, Desvignes, V, Chanteau, MF, Mlika, N & Avril, MF (1992) Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 3: 199–205.
Liu, T & Soong, S-J (1996) Epidemiology of malignant melanoma. Surgical Clinics N Amer 76: 1205–1221.
MacKie, RM, Freudenberger, T & Aitchison, TC (1989) Personal risk-factor chart for cutaneous melanoma. Lancet 2: 487–490.
McCarty, KS Jr, Wortman, J, Stowers, S, Lubahn, DB, McCarty, KS Sr & Seigler, HF (1980) Sex steroid receptor analysis in human melanoma. Cancer 46: 1463–1470.
McClay, EF, Mastrangelo, MJ, Berd, D & Bellet, RE (1992) Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553–556.
McClay, EF, Albright, KD, Jones, JA, Christian, RD & Howell, SB (1993) Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53: 1571–1576.
Mirimanoff, RO, Wagenknecht, L & Hunziger, N (1981) Long-term complete remission of malignant melanoma with tamoxifen. Lancet 1: 1368–1369.
Nesbit, RA, Woods, RL, Tattersall, MH, Tox, RM, Forbes, JF, MacKay, IR & Goodyear, M (1979) Tamoxifen in malignant melanoma [letter]. N Engl J Med 301: 1241–1242.
Osterlind, A, Tucker, MA, Stone, BJ & Jensen, OM (1988a) The Danish case–control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 42: 319–324.
Osterlind, A, Tucker, MA, Stone, BJ & Jensen, OM (1988b) The Danish case–control study of cutaneous malignant melanoma: hormonal and reproductive factors in women. Int J Cancer 42: 821–824.
Palmer, JR, Rosenberg, L, Stron, BL, Harlap, S, Zauber, AG, Warchauer, ME & Shapiro, S (1992) Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 3: 547–554.
Ramcharan, S, Pellegrin, FA, Ray, R & Hsu, JP (1981). The Walnut Creek Contraceptive Drug Study, Vol. III. NIH Publication No 81–564. US Government Printing Office: Washington, DC
Snell, RS & Bischitz, PG (1960) The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol 35: 73–82.
Telhaug, R, Klepp, O & Bormer, O (1982) Phase II study of tamoxifen in patients with metastatic malignant melanoma. Cancer Treat Rep 66: 1437
Wagstaff, J, Thatcher, N, Rankin, E & Crowther, D (1982) Tamoxifen in the treatment of metastatic malignant melanoma. Cancer Treat Rep 66: 1771
Weinstock, MA, Colditz, GA, Willett, WC, Stampfer, MC, Bronstein, BR, Mihm, MC & Speizer, FE (1989) Non-familial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 84: 199–204.
Westerdahl, J, Olsson, H, Masback, A, Ingvar, C & Johsson, N (1996) Risk of malignant melanoma in relation to drug intake, alcohol, smoking, and hormonal factors. Br J Cancer 73: 1126–1131.
Zanetti, R, Franceschi, S, Rosso, S, Bidoli, E & Colonna, S (1990) Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol 19: 522–526.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Feskanich, D., Hunter, D., Willett, W. et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 81, 918–923 (1999). https://doi.org/10.1038/sj.bjc.6690787
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690787
Keywords
This article is cited by
-
Gender-specific associations between polymorphisms of the circadian gene RORA and cutaneous melanoma susceptibility
Journal of Translational Medicine (2021)
-
Correlation between fertility drugs use and malignant melanoma incidence: the state of the art
Tumor Biology (2014)
-
Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues
Cancer Causes & Control (2008)
-
Relation of body mass index to cancer risk in 362,552 Swedish men
Cancer Causes & Control (2006)
-
Malignant melanoma with gall bladder metastasis as a second neoplasm in the course of prostate cancer
Pathology & Oncology Research (2004)